课题基金 / 基金详情

酶响应性纳米介孔硅药物控释系统及生物学评价研究

批准号:
21274169
项目类别:
面上项目
资助金额:
78.0 万元
负责人:
蔡开勇
依托单位:
学科分类:
医用材料化学
结题年份:
2016
批准年份:
2012
项目状态:
已结题
项目参与者:
罗忠、李雯、刘云、侯彦华、丁星伟、李景华、徐大威、张蓓璐、赵璐

项目摘要

结项摘要

项目成果

蔡开勇的其他基金

相似基金

相关文献

中文摘要
针对肝肿瘤治疗中药物利用效率低及毒副作用大的问题,本研究设计了基于肿瘤细胞及其细胞外微环境触发的2类酶响应性纳米介孔硅药物控释系统:金属基质蛋白酶响应性及谷胱甘肽还原酶响应性系统。拟采用天然大分子(羧甲基化壳聚糖、明胶、透明质酸等)及天然蛋白分子(牛血清蛋白、纤维原蛋白等)作为纳米介孔硅封堵剂,提高该系统的生物相容性及降低炎症响应。通过引入靶向分子(叶酸、半乳糖等)及细胞穿膜肽,赋予该系统靶向给药性能及提高细胞吞噬效率。研究酶响应性药物释放性能及规律。从细胞和分子水平系统地探究纳米介孔硅药物控释系统的细胞相容性、细胞内分布、细胞内吞途径(网格蛋白通路等)及机理、炎症响应及机制、抗肿瘤药物(多霉素盐酸盐、阿霉素等)细胞内释放诱导细胞凋亡及机制。以小鼠肿瘤模型探究该系统在肝、肾、脾等器官及肿瘤组织中的分布及靶向性聚集,对肿瘤治疗的抑制作用及机理。为此类药物控释系统的研究提供重要的理论依据。
英文摘要
Considering the issues of low drug efficiency and high toxic side effect during liver tumor therapy, the project designs two types of enzyme responsive controlled drug release systems based on meseoporous silica nanoparticles (MSNs): matrix metalloproteinase responsive and glutathione reductase responsive systems. Those systems would be triggered by enzymes within tumor cells and extracellular microenvironment. Natural polymers (carboxymethyl chitosan, gelatin, hyaluronic acid, etc.) and natural proteins (bovine serum albumin, fibrinogen, etc) would be employed to seal the MSNs as capping agents, which are expected to improve the biocompatibility and reduce the inflammatory responses of the systems. The introduction of targeting molecules (folic acid, galactose, etc.) and cell-penetrating peptides (CPPs) would provide the systems with targeted drug delivery and improve cellular endocytosis efficiency. The study will investigate the enzyme responsive drug release property and its rules. Then, the study will systematically investigate at cellular and molecular levels on the cytocompatibility, intracellular distribution, cellular endocytosis pathways (i. g. clathrin pathway) and its mechanism, inflammatory reaction and its mechanism, intracellular delivery of anti-tumor drug (daunorubicin hydrochloride, doxorubicin etc.) and its induced cell apoptosis as well as mechanism of the MSNs controlled drug release systems. Finally, the study will investigate the distribution and targeted aggregation of the MSNs system within organs (liver, kidney and spleen etc.) and tumor tissue, and their inhibition effects on tumor therapy and the potential mechanism, by employing a naked mouse model. The study would provide important theory reference for the development of the similar controlled drug release system.
肝肿瘤是一种浸袭和转移性、耐药性高的恶性肿瘤,已成为威胁人类身体健康的头号肿瘤。针对肝肿瘤治疗中药物利用效率低及毒副作用大的问题,本项目利用纳米介孔硅载体,研制了基于肿瘤细胞及其肿瘤微环境信号触发的及氧化-还原响应性、金属基质蛋白酶响应性及pH响应性药物控释系统,并在体内外评价了相关系统的生物学响应及分子机制。总体上讲,项目进展顺利,完成情况良好,在纳米药物控释系统一流期刊诸如ACS Nano、 Biomaterials、J Control Release、ACS Appl Mater & Interfaces、Journal of Materials Chemistry B等发表SCI论文18篇,1篇论文入选HCP论文。申请国家发明专利2项,培养博士生5名,硕士生3名,各项指标都超过或成倍合同要求的内容。已取得的研究成果,为今后进一步深入探究纳米药物控释系统用于临床肿瘤治疗打下了坚实的基础。
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
Intracellular redox-activated anticancer drug delivery by functionalized hollow mesoporous silica nanoreservoirs with tumor specificity
具有肿瘤特异性的功能化中空介孔二氧化硅纳米储库的细胞内氧化还原激活抗癌药物递送
DOI: 10.1016/j.biomaterials.2014.05.058
发表时间: 2014-09-01
期刊: BIOMATERIALS
影响因子: 14
作者: [Luo, Zhong, Hu, Yan, Zhao, Yanli]
通讯作者: Zhao, Yanli
DOI: 10.1016/j.biomaterials.2016.01.008
发表时间: 2016-03-01
期刊: BIOMATERIALS
影响因子: 14
作者: [Liu, Junjie, Luo, Zhong, Cai, Kaiyong]
通讯作者: Cai, Kaiyong
Redox-Responsive Nanocarrier Based on Heparin End-Capped Mesoporous Silica Nanoparticles for Targeted Tumor Therapy in Vitro and in Vivo
基于肝素封端介孔二氧化硅纳米粒子的氧化还原响应纳米载体用于体外和体内靶向肿瘤治疗
DOI: 10.1021/la501924p
发表时间: 2014-07-08
期刊: LANGMUIR
影响因子: 3.9
作者: [Dai, Liangliang, Li, Jinghua, Cai, Kaiyong]
通讯作者: Cai, Kaiyong
Engineering a Hollow Nanocontainer Platform with Multifunctional Molecular Machines for Tumor-Targeted Therapy in Vitro and in Vivo
利用多功能分子机器设计中空纳米容器平台,用于体外和体内肿瘤靶向治疗
DOI: 10.1021/nn404676w
发表时间: 2013-11-01
期刊: ACS NANO
影响因子: 17.1
作者: [Luo, Zhong, Ding, Xingwei, Zhao, Yanli]
通讯作者: Zhao, Yanli
18
    生物能供给医用高分子界面材料设计及骨修复研究
    • 批准号:
      52333011
    • 项目类别:
      重点项目
    • 资助金额:
      230万元
    • 批准年份:
      2023
    • 负责人:
      蔡开勇
    • 依托单位:
    医用高分子生物活性表界面与干细胞的相互作用
    • 批准号:
      21734002
    • 项目类别:
      重点项目
    • 资助金额:
      300.0万元
    • 批准年份:
      2017
    • 负责人:
      蔡开勇
    • 依托单位:
    兼具促成骨及抗菌性能钛基植入体生物功能性界面研究
    • 批准号:
      51673032
    • 项目类别:
      面上项目
    • 资助金额:
      65.0万元
    • 批准年份:
      2016
    • 负责人:
      蔡开勇
    • 依托单位:
    层层组装构建钛/钛合金界面微环境的研究
    • 批准号:
      51173216
    • 项目类别:
      面上项目
    • 资助金额:
      58.0万元
    • 批准年份:
      2011
    • 负责人:
      蔡开勇
    • 依托单位:
    国内基金
    海外基金